Consequently, CAD-CHM does not demonstrate cost-effectiveness as a first-line therapy for HER2-negative advanced G/GEJ adenocarcinoma, irrespective of PD-L1 CPS status, from the perspective of the Chinese healthcare system. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.